Fig. 3: Vaccine induces polyclonal effector memory CD8 T cell responses across multiple neoantigens and HLAs.
a, Patient PBMCs from available posttreatment timepoints (G1 W12, G2 W5, G3 W8, G4 W6, G7 W4, G8 W12, G9 W8, G10 W16, G11 W16, G12 W12, G13 W12, G14 W13 and G15 W12) were stimulated overnight in ex vivo or post-IVS IFN-γ ELISpot with patient-specific minipools or DMSO. Graphs show percentage of total response of mean IFN-γ responses to minipool 1 (turquoise), minipool 2 (light blue), minipool 3 (medium blue) and minipool 4 (navy blue) for each patient. b, Number of positive minimal epitopes detected (positive by ex vivo or post-IVS ELISpot) for each mutated gene. Undetectable responses against epitopes tested are indicated by ‘x’. c, Pie charts showing patient-specific predicted HLA class I presentation of positive neoantigen responses shown in panel b. d, Density plots showing recognition of pHLA (A*30:04, A*02:01, B*08:01) and corresponding T cell memory phenotypes for patient G2. Pie charts showing frequencies of naive (CD45RA+CCR7+; purple), central memory (CM; CD45RA−CCR7+; blue), effector memory (EM; CD45RA−CCR7−; green) and T effector memory RA+ (TEMRA; CD45RA+CCR7−; orange) cells in total CD8+ population (left-most chart) and CD8+tetramer+ populations from corresponding dot plots. e, Density plots and corresponding pie charts showing recognition of pHLA (B*44:05) and corresponding T cell memory phenotypes before and after ChAd68 boost for patient G1.
